Severity Level and Duration of Energy Deficit in Mice Affect Bone Phenotype and Bone Marrow Stromal Cell Differentiation Capacity.
bone
bone marrow adiposity
bone marrow stromal cell (BMSC)
differentiation
energy deficit
sirtuin type 1 (SIRT1)
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
02
2022
accepted:
25
04
2022
entrez:
23
6
2022
pubmed:
24
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
Anorexia nervosa is known to induce changes in bone parameters and an increase in bone marrow adiposity (BMA) that depend on the duration and seriousness of the disease. Previous studies have found that bone loss is associated with BMA accumulation. Sirtuin of type 1 (Sirt1), a histone deacetylase that is partly regulated by energy balance, was shown to have pro-osteoblastogenic and anti-adipogenic effects. To study the effects of the severity and duration of energy deficits related to bone loss, a mouse model of separation-based anorexia (SBA) was established. We recently demonstrated that moderate body weight loss (18%) 8-week SBA protocol in mice resulted in an increase in BMA, bone loss, and a significant reduction in Sirt1 expression in bone marrow stromal cells (BMSCs) extracted from SBA mice. We hypothesised that Sirt1 deficit in BMSCs is associated with bone and BMA alterations and could potentially depend on the severity of weight loss and the length of SBA protocol. We studied bone parameters, BMA, BMSC differentiation capacity, and Sirt1 expression after induction of 4 different levels of body weight loss (0%,12%,18%,24%), after 4 or 10 weeks of the SBA protocol. Our results demonstrated that 10 week SBA protocols associated with body weight loss (12%, 18%, 24%) induced a significant decrease in bone parameters without any increase in BMA. BMSCs extracted from 12% and 18% SBA groups showed a significant decrease in Sirt1 mRNA levels before and after co-differentiation. For these two groups, decrease in Sirt1 was associated with a significant increase in the mRNA level of adipogenic markers and a reduction of osteoblastogenesis. Inducing an 18% body weight loss, we tested a short SBA protocol (4-week). We demonstrated that a 4-week SBA protocol caused a significant decrease in Tb.Th only, without change in other bone parameters, BMA, Sirt1 expression, or differentiation capacity of BMSCs. In conclusion, this study showed, for the first time, that the duration and severity of energy deficits are critical for changes in bone parameters, BMSC differentiation, and Sirt1 expression. Furthermore, we showed that in this context, Sirt1 expression could impact BMSC differentiation with further effects on bone phenotype.
Identifiants
pubmed: 35733777
doi: 10.3389/fendo.2022.880503
pmc: PMC9207532
doi:
Substances chimiques
RNA, Messenger
0
Sirtuin 1
EC 3.5.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
880503Informations de copyright
Copyright © 2022 Avilkina, Leterme, Falgayrac, Delattre, Miellot, Gauthier, Chauveau and Ghali Mhenni.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biomaterials. 2008 Feb;29(5):573-9
pubmed: 17980905
EMBO Mol Med. 2013 Mar;5(3):430-40
pubmed: 23364955
Bone. 2019 Oct;127:135-145
pubmed: 31146035
Cell Metab. 2014 Aug 5;20(2):368-375
pubmed: 24998914
Endocrinology. 2014 Sep;155(9):3508-15
pubmed: 24949665
Hum Gene Ther. 2010 Sep;21(9):1057-66
pubmed: 20649485
Ann Intern Med. 2000 Nov 21;133(10):790-4
pubmed: 11085841
Am J Clin Pathol. 2002 Oct;118(4):582-8
pubmed: 12375646
J Bone Miner Res. 2006 Jul;21(7):993-1002
pubmed: 16813520
J Bone Miner Metab. 2008;26(3):203-12
pubmed: 18470659
Bone. 2019 Oct;127:343-352
pubmed: 31276849
J Bone Miner Res. 2011 Oct;26(10):2552-63
pubmed: 21713995
J Appl Physiol (1985). 2012 Dec 1;113(11):1792-801
pubmed: 22995391
PLoS One. 2017 Sep 22;12(9):e0185236
pubmed: 28937996
Biomed Res Int. 2014;2014:783459
pubmed: 25243179
Aging Cell. 2004 Dec;3(6):379-89
pubmed: 15569355
Oncotarget. 2015 Jun 30;6(18):15902-30
pubmed: 26079539
Radiology. 1989 Mar;170(3 Pt 1):835-8
pubmed: 2916039
J Bone Miner Res. 2016 Jan;31(1):116-28
pubmed: 26211746
J Bone Miner Res. 2010 Jul;25(7):1616-26
pubmed: 20200969
Exp Gerontol. 2008 Dec;43(12):1086-93
pubmed: 18799131
PLoS One. 2011;6(9):e24307
pubmed: 21931678
J Bone Miner Res. 2012 Nov;27(11):2344-58
pubmed: 22729939
Science. 2004 Jul 16;305(5682):390-2
pubmed: 15205477
J Bone Miner Res. 2010 Feb;25(2):298-304
pubmed: 19653811
Arch Intern Med. 2005 Mar 14;165(5):561-6
pubmed: 15767533
PLoS One. 2014 Aug 04;9(8):e103775
pubmed: 25090643
Science. 1999 Apr 2;284(5411):143-7
pubmed: 10102814
PLoS One. 2012;7(4):e35712
pubmed: 22539994
J Bone Miner Res. 2010 Sep;25(9):2078-88
pubmed: 20229598
Calcif Tissue Int. 2018 Aug;103(2):189-197
pubmed: 29383407
J Cell Biol. 2002 Oct 14;159(1):135-46
pubmed: 12379805
Bone. 2020 Jul;136:115361
pubmed: 32289519
Aging Cell. 2007 Dec;6(6):759-67
pubmed: 17877786
BMC Cell Biol. 2015 Mar 13;16:9
pubmed: 25887471
J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2031-2036
pubmed: 32298404
J Cell Sci. 1992 Jun;102 ( Pt 2):341-51
pubmed: 1400636
Cell Death Dis. 2013 Oct 03;4:e832
pubmed: 24091675
Endocrinology. 2016 Feb;157(2):508-21
pubmed: 26696121
Nat Commun. 2010 Apr 12;1:3
pubmed: 20975665
J Clin Endocrinol Metab. 2009 Jun;94(6):2129-36
pubmed: 19318450
Crit Rev Eukaryot Gene Expr. 2011;21(2):101-13
pubmed: 22077150
J Cell Sci Suppl. 1988;10:63-76
pubmed: 3077943